3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
10
Leukemia, Myeloid, Accelerated Phase
5
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
5
Leukemia
5
Blast Crisis
5
Leukemia, Myeloid, Chronic-Phase
3
Leukemia, Myeloid, Acute
2
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
1
Neoplasms by Histologic Type
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myeloid
1
Hematologic Diseases
1
Burkitt Lymphoma
1
Bone Marrow Diseases
1
Interventions
fludarabine
4
Cyclophosphamide
4
Cisplatin
4
pembrolizumab
3
atezolizumab
3
Pemetrexed
3
fludarabine phosphate
2
entrectinib
2
durvalumab
2
cobimetinib
2
capmatinib
2
alectinib
2
Whole-Body Irradiation
2
Vemurafenib
2
Tacrolimus
2
Peripheral Blood Stem Cell Transplantation
2
Patient Reported Outcome Measures
2
Paclitaxel
2
Nivolumab
2
Mycophenolic Acid
2
Mesna
2
Melphalan
2
Busulfan
2
130-nm albumin-bound paclitaxel
2
trametinib
1
spartalizumab
1
ruxolitinib
1
repotrectinib
1
pralsetinib
1
ponatinib
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Neoplasms by Histologic Type
×
ponatinib
×
1 year
×
Clear all
NCT02467270
2026-03-17
OPTIC
Takeda
Phase 2
Completed
283 enrolled
31 charts